Sign In
Buy CSTL
$24.69
-0.795 (-3.12%)
At Close: Jul 24, 2026
Castle Biosciences Named One of Newsweek's America's Greatest Companies 2025
07:00am, Wednesday, 17'th Sep 2025
FRIENDSWOOD, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has been included in the i
FRIENDSWOOD, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new d
Castle Biosciences: Strong Margins, Solid Balance Sheet, And Big Upside Potential
09:14am, Tuesday, 02'nd Sep 2025
Castle Biosciences effectively translates complex diagnostics into a scalable, high-margin business, with strong clinical demand and a robust balance sheet supporting long-term growth. The investment
New validation study shows DecisionDx-SCC significantly outperforms current staging systems in predicting risk of local recurrence and metastasis for NCCN high-risk patients Clinician survey confirms
Castle Biosciences to Participate in Upcoming Investor Conferences
07:00am, Thursday, 21'st Aug 2025
FRIENDSWOOD, Texas, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its ex
Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript
10:21pm, Monday, 04'th Aug 2025
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Camilla Zuckero - Vice President of Investor Relations & Corporate Affairs Derek
Castle (CSTL) Q2 Revenue Tops Estimates
08:50pm, Monday, 04'th Aug 2025
Castle (CSTL) Q2 Revenue Tops Estimates
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates
06:21pm, Monday, 04'th Aug 2025
Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.51 per share. This compares to earnings of $0.31 per share a y
Castle Biosciences Reports Second Quarter 2025 Results
04:05pm, Monday, 04'th Aug 2025
Delivered Q2 2025 revenue of $86 million Q 2 2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 33% over Q 2 2024 Raising full-year 2025 revenue
New Strong Sell Stocks for August 1st
06:16am, Friday, 01'st Aug 2025
CRSP, CSTL and SIGI have been added to the Zacks Rank #5 (Strong Sell) List on August 1, 2025.
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
07:00am, Tuesday, 29'th Jul 2025
Castle Biosciences' executive management will present a company overview at the Canaccord Genuity 45th Annual Growth Conference Aug. 12, 2025 at 12:30pm ET
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline
11:06am, Monday, 28'th Jul 2025
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
07:00am, Friday, 25'th Jul 2025
FRIENDSWOOD, Texas, July 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its fo
FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx®-Melanoma Test
07:00am, Wednesday, 23'rd Jul 2025
Castle announced that its DecisionDx®-Melanoma test has been granted Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture
07:00am, Thursday, 17'th Jul 2025
FRIENDSWOOD, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has
